Ultrasound plus immune treatment after new glioblastoma diagnosis
Treatments studied
Part of Cancer clinical trials.
This trial tests whether using focused ultrasound to help adjust the immune system can improve outcomes for people with newly diagnosed glioblastoma. You’d already complete standard brain radiation (with or without temozolomide), then undergo an ultrasound-based immune modulation approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older with a new, confirmed glioblastoma diagnosis (pathology proven).
- Your tumor must have IDH1/IDH2 wild-type and an unmethylated MGMT gene promoter.
- Have leftover tumor tissue available (paraffin-embedded sample) for study testing.
- Finish standard radiation therapy (with or without temozolomide) before joining.
- Be able to get contrast-enhanced MRI and perform daily activities at a level of 2 or less on the study’s scale.
- Your tumor location must be treatable by ultrasound (coverable by the ultrasound field).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This trial tests a new way to take a tiny tissue sample from a suspected glioblastoma using ultrasound, to improve noninvasive detection. You may be able to get this targeted sample while you’re already planning surgery for tumor removal.
This trial tests a new treatment called sonodynamic therapy that uses sound waves and a special drug to target brain tumors that have come back. It aims to see if this approach is safe and can shrink tumors in people who are eligible for surgery.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
This trial tests a cancer-immunotherapy medicine (an anti–PD-1 antibody, similar to pembrolizumab) combined with precisely targeted radiation to treat glioblastoma that has come back or progressed. It may help your immune system recognize and attack the tumor while the radiation targets the cancer.
This trial tests whether a special ultrasound (LIFU) can open the blood-brain barrier to help an immunotherapy drug (cetuximab) reach glioblastoma tumors better. It is for people with a specific type of glioblastoma that has not been treated yet and that has a certain protein called EGFR.
Hear when a new Newly Diagnosed Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.